Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.47)
# 945
Out of 5,044 analysts
226
Total ratings
46.01%
Success rate
20.84%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $6.55 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $22.62 | +23.78% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $138.13 | +8.59% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $133.51 | +14.60% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $14.00 | - | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $57.24 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $17.20 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $31.63 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $29.64 | +95.68% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $31.00 | +38.71% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $61.97 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.54 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $147.38 | +5.17% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.13 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $16.92 | +106.86% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.58 | +132.97% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.15 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.59 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.87 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.96 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.36 | +59.18% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $42.06 | +18.88% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.92 | -15.54% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.35 | +1,057.74% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.27 | +214.96% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $42.53 | +36.37% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.86 | +59,039.78% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $9.37 | +753.79% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.17 | +156.41% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $8.10 | +35.80% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.81 | +36.21% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.52 | +1,871.83% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.36 | +747.46% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $20.89 | +857.40% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.49 | +168.46% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $3.58 | +570.39% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $2.58 | +5,481.40% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.28 | +212.50% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $65.40 | -40.37% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $71.56 | -79.04% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.59 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $4.06 | +4,333.50% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.55
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.62
Upside: +23.78%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $138.13
Upside: +8.59%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $133.51
Upside: +14.60%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $14.00
Upside: -
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $57.24
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.20
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.63
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $29.64
Upside: +95.68%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $31.00
Upside: +38.71%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $61.97
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.54
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $147.38
Upside: +5.17%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.13
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $16.92
Upside: +106.86%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.58
Upside: +132.97%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.15
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.87
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.96
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.36
Upside: +59.18%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $42.06
Upside: +18.88%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.92
Upside: -15.54%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.35
Upside: +1,057.74%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.27
Upside: +214.96%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $42.53
Upside: +36.37%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.86
Upside: +59,039.78%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $9.37
Upside: +753.79%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.17
Upside: +156.41%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $8.10
Upside: +35.80%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.81
Upside: +36.21%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.52
Upside: +1,871.83%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.36
Upside: +747.46%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $20.89
Upside: +857.40%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.49
Upside: +168.46%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $3.58
Upside: +570.39%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $2.58
Upside: +5,481.40%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.28
Upside: +212.50%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $65.40
Upside: -40.37%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $71.56
Upside: -79.04%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.59
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $4.06
Upside: +4,333.50%